Cara Therapeutics, Inc. (0HTC.L)
USD 5.33
(-0.22%)
USD 5.33
(-0.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 14.79 Million USD | -57.99% |
| 2022 | 34.6 Million USD | 61.13% |
| 2021 | 21.47 Million USD | -23.34% |
| 2020 | 28.01 Million USD | 130.03% |
| 2019 | -93.27 Million USD | -50.3% |
| 2018 | -62.06 Million USD | -30.35% |
| 2017 | -47.61 Million USD | 3.16% |
| 2016 | -49.16 Million USD | -182.28% |
| 2015 | -17.41 Million USD | -46.48% |
| 2014 | -11.89 Million USD | -462.64% |
| 2013 | 3.27 Million USD | 548.56% |
| 2012 | -731 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 914 Thousand USD | -32.72% |
| 2024 Q1 | 1.47 Million USD | -36.34% |
| 2023 Q3 | 3.3 Million USD | -40.02% |
| 2023 Q1 | 3.57 Million USD | 216.09% |
| 2023 FY | 14.53 Million USD | -57.99% |
| 2023 Q2 | 5.51 Million USD | 54.27% |
| 2023 Q4 | 2.31 Million USD | -30.05% |
| 2022 FY | 34.6 Million USD | 61.13% |
| 2022 Q4 | 1.13 Million USD | -85.42% |
| 2022 Q3 | 7.75 Million USD | -65.66% |
| 2022 Q2 | 22.58 Million USD | 733.85% |
| 2022 Q1 | 2.7 Million USD | 541.94% |
| 2021 Q4 | 422 Thousand USD | -91.13% |
| 2021 Q2 | -384 Thousand USD | 97.77% |
| 2021 FY | 21.47 Million USD | -23.34% |
| 2021 Q1 | -17.19 Million USD | -121.62% |
| 2021 Q3 | 4.75 Million USD | 1339.06% |
| 2020 Q4 | 79.53 Million USD | 892.73% |
| 2020 Q3 | -10.03 Million USD | 51.0% |
| 2020 Q2 | -20.47 Million USD | 19.53% |
| 2020 Q1 | -25.44 Million USD | -0.35% |
| 2020 FY | 28.01 Million USD | 130.03% |
| 2019 Q1 | -19.22 Million USD | -11.35% |
| 2019 FY | -93.27 Million USD | -50.3% |
| 2019 Q2 | -19.14 Million USD | 0.41% |
| 2019 Q3 | -30.2 Million USD | -57.76% |
| 2019 Q4 | -25.35 Million USD | 16.07% |
| 2018 FY | -62.06 Million USD | -30.35% |
| 2018 Q4 | -17.26 Million USD | -0.15% |
| 2018 Q3 | -17.24 Million USD | -22.03% |
| 2018 Q2 | -14.12 Million USD | -5.22% |
| 2018 Q1 | -13.42 Million USD | -15.99% |
| 2017 Q3 | -9.15 Million USD | -31.46% |
| 2017 Q2 | -6.96 Million USD | 65.06% |
| 2017 Q4 | -11.57 Million USD | -26.5% |
| 2017 Q1 | -19.92 Million USD | 1.74% |
| 2017 FY | -47.61 Million USD | 3.16% |
| 2016 Q2 | -10.68 Million USD | -25.08% |
| 2016 FY | -49.16 Million USD | -182.28% |
| 2016 Q4 | -20.27 Million USD | -109.67% |
| 2016 Q3 | -9.67 Million USD | 9.46% |
| 2016 Q1 | -8.53 Million USD | -12.83% |
| 2015 Q3 | -3.14 Million USD | 17.48% |
| 2015 Q2 | -3.81 Million USD | -31.56% |
| 2015 Q1 | -2.89 Million USD | -13.79% |
| 2015 FY | -17.41 Million USD | -46.48% |
| 2015 Q4 | -7.56 Million USD | -140.71% |
| 2014 Q1 | -2.02 Million USD | -569.87% |
| 2014 Q3 | -5.08 Million USD | -126.92% |
| 2014 Q4 | -2.54 Million USD | 49.93% |
| 2014 FY | -11.89 Million USD | -462.64% |
| 2014 Q2 | -2.24 Million USD | -10.73% |
| 2013 Q2 | 9.28 Million USD | 1106.83% |
| 2013 Q4 | -302 Thousand USD | 84.24% |
| 2013 Q1 | -922 Thousand USD | -112.93% |
| 2013 FY | 3.27 Million USD | 548.56% |
| 2013 Q3 | -1.91 Million USD | -120.64% |
| 2012 FY | -731 Thousand USD | 0.0% |
| 2012 Q4 | -433 Thousand USD | 30.05% |
| 2012 Q3 | -619 Thousand USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 114.864% |
| Dynavax Technologies Corporation | 182.11 Million USD | 91.877% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.944% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 97.175% |
| Perrigo Company plc | 1.68 Billion USD | 99.12% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 4826.518% |
| Illumina, Inc. | 2.74 Billion USD | 99.461% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.903% |
| Nektar Therapeutics | 53.47 Million USD | 72.336% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 254.652% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 99.718% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -47.321% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 175.1% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.223% |
| Waters Corporation | 1.76 Billion USD | 99.16% |
| Biogen Inc. | 7.3 Billion USD | 99.797% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 132.64% |
| Adicet Bio, Inc. | -6.09 Million USD | 342.604% |
| Evolus, Inc. | 140.52 Million USD | 89.472% |
| bluebird bio, Inc. | -4.03 Million USD | 467.097% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 117.361% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 79.753% |
| FibroGen, Inc. | 128.9 Million USD | 88.523% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 99.573% |
| Homology Medicines, Inc. | -7.22 Million USD | 304.648% |
| Geron Corporation | -123.5 Million USD | 111.979% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.025% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 147.466% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 95.914% |
| Myriad Genetics, Inc. | 476.4 Million USD | 96.895% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.869% |
| OPKO Health, Inc. | 318.12 Million USD | 95.35% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 5166.438% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 103.71% |
| Zoetis Inc. | 5.83 Billion USD | 99.746% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -4798.675% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.318% |
| Exelixis, Inc. | 1.75 Billion USD | 99.158% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.828% |
| uniQure N.V. | 2.21 Million USD | -567.901% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 4982.508% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 93.95% |
| Verastem, Inc. | -62 Thousand USD | 23961.29% |
| Imunon, Inc. | -720 Thousand USD | 2154.708% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 98.1% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 98.646% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.199% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 96.891% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 97.677% |
| TG Therapeutics, Inc. | 219.1 Million USD | 93.248% |
| Blueprint Medicines Corporation | 236.58 Million USD | 93.747% |
| Insmed Incorporated | 239.63 Million USD | 93.826% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 14.579% |
| Incyte Corporation | 3.44 Billion USD | 99.57% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 95.698% |